Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26103771 | 1.00 | MGLL (0.35) | MGLL | |
| SCHEMBL26103737 | 1.00 | MGLL (0.35) | MGLL | |
| SCHEMBL26105568 | 0.91 | MGLL (0.31) | MGLL | |
| SCHEMBL17112985 | 0.87 | SMYD3 (0.30) | — | |
| SCHEMBL19212832 | 0.87 | SMYD3 (0.30) | — | |
| SCHEMBL21051957 | 0.85 | — | — | |
| SCHEMBL30392021 | 0.79 | MAPT (0.44) | — | |
| SCHEMBL30390929 | 0.79 | MAPT (0.44) | — | |
| SCHEMBL23150442 | 0.78 | MGLL (0.54) | MGLL | |
| SCHEMBL21382067 | 0.78 | MGLL (0.54) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2344473-B1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2262802-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2344473-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| EP-2262802-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MGLL 4209/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGLL 4414/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGLL 4209/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MGLL 4414/4885 |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | MGLL 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.